Nerve conduction studies (NCS) are necessary to distinguish multifocal motor neuropathy (MMN) from other disorders with a similar clinical picture. In MMN, NCS may show a unique combination of conduction block (CB) or conduction slowing consistent with demyelination, whereas sensory conduction in the same nerve is normal. This contribution discusses a relatively simple and practical electrophysiological approach for the diagnosis of MMN that can be used by any neurologist who has had training in NCS. When diagnosing MMN, the most important practical points are: careful stimulation technique, investigation according to a standardised protocol that includes at least five nerves per arm with stimulation up to Erb's point, understanding of and adherence to criteria for conduction block and demyelinative slowing and exclusion of nerves with marked axon loss.
due to unintended co-stimulation of other nerves that lie nearby.
The recommended technique is summarised in Table 1 and Figure 1 . The standard stimulus duration of 0.2 ms is often insufficient to achieve the required supramaximal stimulation. To avoid an unnecessary number of stimuli before supramaximal stimulation is achieved, it is wise to set the stimulus duration for stimulation at Erb's point at 1.0 ms.
Supramaximal stimulation cannot always be achieved, especially at
Erb's point. This may be due to obesity, anatomical features such as compact stature, or decreased nerve excitability due to the disease process. Two examples will be given. In the first example, the CMAP at Erb's point is 2 mV with stimulation at 60 mA, 3 mV with stimulation at 70 mA, 4 mV with stimulation at 80 mA, 5 mV with stimulation at 90 mA and 6 mV with stimulation at 100 mA. This indicates that neither maximal nor supramaximal stimulation was achieved, because the CMAP continued to increase when stimulus-current was increased. Since supramaximal stimulation was not possible, the CMAP at Erb's point cannot be properly judged. In the second example, the CMAP at Erb's point is 3 mV with stimulation at 60 mA, 4 mV with stimulation at 70 mA, 4 mV with stimulation at 80 mA, 4 mV with stimulation at 90 mA and 4 mV with stimulation at 100 mA. This indicates that maximal stimulation was achieved at 70 mA and that by adding 30 % of stimulus-current, supramaximal stimulation did not result in a further CMAP increase. Since supramaximal stimulation was achieved, this CMAP can be taken into account.
Recommended Protocol
In its most extensive form, the recommended protocol for NCS in the diagnosis of MMN consists of bilaterally performed motor and sensory NCS, using standard surface electrodes for stimulation and recording (see Table 2 ). Motor NCS are performed in order to detect motor CB, demyelinative slowing in motor axons, or loss of motor axons (see Figure 2 ). Sensory NCS serve two purposes:
• sensory nerve action potentials (SNAPs) are recorded to rule out involvement of peripheral sensory axons. Decreased SNAPs may point to a sensorimotor neuropathy (e.g. Lewis-Sumner syndrome), brachial plexus involvement, or peripheral nerve pathology other than MMN; and • normal sensory conduction over a nerve segment with conduction block or demyelinative slowing on motor NCS, strongly supports the diagnosis of MMN (see Figure 2 ). In MMN patients, the diagnostic yield for finding CB or slowing compatible with demyelination was found to be greatest for nerves innervating hand muscles, followed, in order of decreasing diagnostic yield, by nerves innervating forearm or upper arm muscles and nerves innervating foot muscles. 2 In another study, using different criteria for CB and slowing, no differences between upper and lower limb nerves were found. Figure 2) . This is because a part of the action potentials that are evoked at the proximal site will not pass the site where they are blocked, whereas all action potentials evoked at the distal site will reach the muscle.
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At least three mechanisms other than CB may also give rise to an abnormally large segmental CMAP reduction:
• increased temporal dispersion, defined as an increased difference in conduction time between the axons within a nerve, leads to desynchronised activation of the MUPs that form the CMAP. Since this desynchronisation is more pronounced on proximal than on distal stimulation, the CMAP on proximal stimulation will be lower and broader than the CMAP on distal stimulation. In NCS, temporal dispersion is usually measured by comparing the duration of the CMAP evoked on proximal stimulation with the duration of the CMAP evoked on distal stimulation of a nerve segment;
• increased temporal dispersion gives rise to cancellation between positive and negative phases of the MUPs out of which the CMAP is built (phase cancellation). Because temporal dispersion is more pronounced after more proximal stimulation, phase cancellation is also more pronounced after more proximal stimulation; and
• if the MUPs that form the CMAP are polyphasic due to partial loss of motor axons followed by collateral sprouting, phase cancellation may become more prominent. This mechanism seems unlikely, however, as simultaneous recording of MUPs by surface and needle electrodes showed no polyphasic surface recorded MUPs, even when its needle-recorded counterpart is polyphasic.
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Because CB has to be distinguished from the other mechanisms causing increased segmental CMAP reduction, criteria are required.
Some studies have derived criteria for CB by comparing segmental CMAP changes in MMN patients, chronic inflammatory demyelinating polyneuropathy (CIDP) patients, motor neurone disease (MND) patients, and normal subjects. Multifocal Motor Neuropathy There is, however, no scientific basis for the amount of detail in these criteria and the AAEM criteria identified fewer patients with proven MMN than simpler criteria.
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In another simulation study, CMAPs were reconstructed from surface MUPs recorded from human hand muscles and the effects of temporal dispersion in the relevant and adjacent segments simulated. 5 This showed that less stringent criteria for CB are indeed possible if temporal dispersion is limited (see Table 3 ). For instance, if the duration of the wrist CMAP is normal (<9 ms) and if there is no duration prolongation in the forearm segment where CB has to be assessed, the criterion for CB is a segmental area reduction of at least 25 %. However, with a duration prolongation of 3-5 ms in the forearm segment, the criterion for CB is a segmental area reduction of at least 55 %. Table 3 also shows that criteria for CB become less stringent when wrist CMAP duration becomes longer. This is because temporal dispersion has already occurred in the segment between wrist and muscle so that its effects will be less pronounced in the forearm segment. The Van Asseldonk criteria 5 can be applied to median and ulnar nerve NCS with recording from hand muscles and require that CMAP area and duration are measured from the total area of all negative phases; this option can be installed on most commercial electromyography apparatus.
In conclusion, the above described evidence may suggest the following approach for the detection of CB (see also Practical Considerations):
start with the Rhee-criterion; if this is fulfilled, definite CB has been diagnosed. If the Rhee criterion is not fulfilled, apply the Van Asseldonk criteria and if these are not fulfilled, apply the criterion for possible CB.
Criteria for Demyelinative Slowing
To distinguish nerve conduction slowing due to demyelination from slowing due to dysfunction of axons or loss of fast conducting axons, criteria are needed. Early criteria for demyelinative slowing were derived by comparing motor and sensory conduction velocity in demyelinating Charcot-Marie-Tooth (CMT) neuropathy with those in axonal CMT neuropathy. 13 Demyelinating and axonal forms were distinguished by findings on nerve biopsy. The cut-off value that distinguished both forms was 60 % of the normal mean; for an upper limb nerve this corresponds to approximately 38 m/s. In demyelinating CMT all conduction velocities were below this value and in axonal CMT they were above this value. Thus, in a patient with CMT neuropathy, a value below 60 % indicates demyelinating CMT and a value above 60 % axonal CMT.
These criteria were later modified by defining a percentage below the lower limit of normal (or above the upper limit of normal) for various NCS variables that are affected by conduction slowing, including motor conduction velocity (MCV), distal motor latency (DML), shortest
F-M interval and segmental CMAP duration prolongation. For instance, MCV was considered compatible with demyelination if its
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Negative peak CMAP amplitude on stimulation of the distal part of the segment with motor CB must be >20 % of the lower limit of normal and >1mV.
Increase of proximal to distal negative peak CMAP duration must be ≤30 % Nerve temperature is an important variable to take into account, because both cold and demyelination may give rise to nerve conduction slowing (see 'Practical Considerations'). It is, therefore, more accurate to carry out NCS when nerve temperature is 37 °C.
Criteria for demyelinative slowing are available when nerves are investigated after warming the limbs in water at 37 °C for at least 30 minutes; this procedure ensures that nerve temperature is close to 37 °C 14,15 (see Table 4 ). These criteria were made for several motor nerve conduction variables, including DML, MCV, minimal F-M latency and segmental CMAP duration prolongation and are applicable to the median, ulnar, peroneal and tibial nerves to hand or foot muscles.
They were derived by assessing the maximal slowing due to axon loss patients with motor neurone disease and are based on the assumption that demyelination can be assumed if slowing exceeds the maximal slowing that may occur due to axon loss.
Criteria for Multifocal Motor Neuropathy
After studying the available evidence, a EFNS/PNS joint task force developed consensus electrophysiological criteria for the diagnosis of MMN (see Table 5 and 6). 10 However, the EFNS/PNS criteria may lead to underdiagnosis of MMN because they require at least two segments with possible CB, if definite CB cannot be shown.
Our practice is to use criteria that are based on the response to intravenous immunoglobulin (IVIg), currently the gold-standard treatment of MMN. 1 A prospective study of 37 patients with lower motor neurone loss and features of demyelination on NCS showed that the response to IVIg depended on the electrophysiological findings.
Patients were investigated according to the above described, extensive standardised NCS protocol. The percentage of patients who responded favourably to IVIg was 81 % if there was at least one segment with definite CB, 71 % if there was no definite CB, but at least one segment with possible CB and 11 % if there was demyelinative slowing without CB. The criteria, derived from these findings, are shown in Table 7 .
IVIg did not induce improvement in five patients with a clinical picture of MMN without CB or demyelinative slowing. 16 Although this appears to suggest that MMN without CB or demyelinative slowing does not exist, the author investigated two patients with a lower motor neurone syndrome without CB or demyelinative slowing who responded favourably to IVIg. In one of these patients, subsequent NCS revealed CB. Another study described patients with a lower motor neurone syndrome who, despite lack of CB or demyelinative slowing, improved on IVIg treatment. 17 However, these patients did not undergo the extensive NCS protocol as described below. If the extensive NCS protocol does not show CB or demyelinative slowing in a patient with a clinical picture of MMN, a trial IVIg course of 2 g/kg
Multifocal Motor Neuropathy in one nerve (see Table 5 )
Probable MMN
Clinical criteria 1, 2 and 8-11 and electrophysiological criteria 2 and 3 in two nerves (see Table 5 ); clinical criteria 1, 2 and 8-11
and electrophysiological criteria 2 and 3 in one nerve and at least two supportive criteria 1-4 (see Table 5 )
Possible MMN
Clinical criteria 1, 2 and 8-11 and normal sensory nerve conduction studies and supportive criteria 4; clinical criteria 1 with clinical signs present in only one nerve, clinical criteria 2 and 8-11 and electrophysiological criteria 1 or 2 and 3 in one nerve (see Table 5 
Practical Considerations
When conducting electrophysiological studies in a patient suspected of having MMN, the above suggests the following practical considerations :
• use the simple Rhee criterion for definite CB: segmental area reduction of >50 %. As this criterion already takes temporal dispersion into account there is no justification in requiring limited temporal dispersion as suggested in some consensus criteria;
• start with motor NCS, on both sides, of the median, ulnar, radial, and musculocutaneous nerves up to Erb's point. The median nerve should be assessed to the thenar and forearm muscles;
• if there is at least one segment with definite motor CB and sensory conduction over this segment is normal, the electrophysiological investigation is consistent with MMN;
• if only possible CB is found in the median or ulnar nerve to the hand, assess if the segmental CMAP reduction is consistent with CB according to the Van Asseldonk criteria (see Table 3 ). If so, the diagnosis of MMN is more likely;
• if no CB is found in upper limbs, extend motor NCS to the peroneal and tibial nerves on both sides. Note that for these nerves only the Rhee criterion is applicable and that evidence-based criteria for possible CB are not available;
• judge CB from measurement of CMAP area and not from CMAP amplitude;
• do not judge CB and do not judge demyelinative slowing if the CMAP on distal stimulation of the segment is below 1 mV (baseline-negative peak);
• needle electromyography in patients with MMN may show prominent signs of denervation and re-innervation, also in non-atrophic muscles. 3 Thus, the finding of prominent needle EMG abnormalities does not favour motor neurone disease over MMN;
• if the NCS protocol does not show CB or demyelinative slowing in a patient with a clinical picture of MMN, repeat NCS after one year or after progression of weakness; and
• it is strongly recommended to warm the limbs in water at 37 °C for at least 30 minutes before NCS to ensure that the investigated nerves reach a temperature of 37 °C. 14, [18] [19] [20] [21] Warming nerves to this temperature increases the detection of CB because nodal sodium channels have a shorter open time at higher temperatures, increasing the probability that conduction at critically demyelinated internodes will become blocked. 19, 22 Furthermore, CV slowing due to cold can be distinguished from CV slowing due to demyelination.
Correcting a measured CV value for limb temperature by recalculating it for 37 °C (using the relation 2.2 m/s/°C) is not appropriate since correction factors in diseased nerves differ from those measured in normal subjects. 20, 21 Warming limbs by infrared heaters is not recommended since it takes an extraordinary amount of time to reach the desired nerve temperature. 18 The usefulness of warming by blankets has not yet sufficiently been proven.
Conclusion
MMN is a rare, acquired, immune-mediated neuropathy that responds to treatment with IVIg. Accurate differential diagnosis using electrophysiological investigation is essential in patients presenting with clinical signs and symptoms suggestive of MMN. By following the practical steps outlined in this article, the relevant NCS can be carried out by any appropriately trained neurologist. n Practical Electrophysiology for the Diagnosis of Multifocal Motor Neuropathy 
